Virtual Library

Start Your Search

  • ELCC 2017

    The 7th European Lung Cancer Conference

    Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland

    Presentation Date(s):  
    • May 5 – 8, 2017
    • Total Presentations: 359

Filter Results:

Show Only Available Presentations

  • +

    The role of antiangiogenic agents in NSCLC: Are we making progress?

    • Type: Young Oncologist session
    • Presentations: 3
    • Moderators:M. Reck
    • Coordinates: 5/07/2017, 08:00 - 08:50, Room X
    • +

      State of the art in first and subsequent lines of the NSCLC treatment

      08:00 - 08:20  |  Author(s): B. Besse

      • Abstract

      Abstract not provided

    • +

      Biomarker approaches for optimisation of antiangiogenic therapy

      08:20 - 08:40  |  Author(s): M. Reck

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Discussion

      08:40 - 08:50

      • Abstract

      Abstract not provided

  • +

    Management of NSCLC with resistance to first line targeted therapy

    • Type: Educational session
    • Presentations: 5
    • Moderators:L. Horn
    • Coordinates: 5/07/2017, 09:00 - 10:30, Room B
    • +

      Management of T790M positive disease after EGFR TKI failure

      09:00 - 09:20  |  Author(s): L. Horn

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Management of T790M negative disease after EGFR TKI failure

      09:20 - 09:40  |  Author(s): M. Krebs

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Management of drug resistance in ALK positive NSCLC

      09:40 - 10:00  |  Author(s): D.S. Tan

      • Abstract

      Abstract not provided

    • +

      Management of resistance in other targets beyond ALK and EGFR

      10:00 - 10:20  |  Author(s): L. Friboulet

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Questions and Answers

      10:20 - 10:30

      • Abstract

      Abstract not provided

  • +

    SCLC and early stage NSCLC

    • Type: Proffered Paper session
    • Presentations: 7
    • +

      44O - Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non-small cell lung cancer: A SEER database analysis

      09:00 - 09:12  |  Author(s): O. Abdel-Rahman

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      59O - The impact of EGFR mutations on the prognosis of resected non-small cell lung cancer: A meta-analysis of literatures

      09:12 - 09:24  |  Author(s): W. Liang

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      60O - The benchmark of examined lymph node count in node positive NSCLC patients: A populational validation with SEER database

      09:24 - 09:36  |  Author(s): W. Liang

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Invited Discussant 44O, 59O and 60O

      09:36 - 09:51  |  Author(s): W.E.E. Eberhardt

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      51O - Early limited-stage small cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial

      09:51 - 10:03  |  Author(s): A. Salem

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      LBA2_PR - Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: Results from the Phase III CONVERT trial

      10:03 - 10:15  |  Author(s): F. Gomes

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Invited Discussant 51O and LBA2_PR

      10:15 - 10:30  |  Author(s): S. Popat

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC?

    • Type: Controversy session
    • Presentations: 4
    • Moderators:M. Reck
    • Coordinates: 5/07/2017, 09:15 - 10:15, Room A
    • +

      Introduction and first vote

      09:15 - 09:25  |  Author(s): M. Reck

      • Abstract

      Abstract not provided

    • +

      Yes

      09:25 - 09:45  |  Author(s): R. Herbst

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      No

      09:45 - 10:05  |  Author(s): B. Besse

      • Abstract

      Abstract not provided

    • +

      Second vote and conclusions

      10:05 - 10:15  |  Author(s): L. Paz-Ares

      • Abstract

      Abstract not provided

  • +

    Molecular understanding of lung cancer: The role of the host and environment

    • Type: Educational session
    • Presentations: 5
  • +

    SCLC: New insights

    • Type: Educational session
    • Presentations: 5
    • +

      What is the optimal thoracic radiotherapy in limited stage SCLC?

      11:00 - 11:20  |  Author(s): C. Faivre-Finn

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Can brain control be improved beyond PCI?

      11:20 - 11:40  |  Author(s): E. Gkika

      • Abstract

      Abstract not provided

    • +

      New therapies, new era?

      11:40 - 12:00  |  Author(s): N. Reguart

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      What can CDX models teach us?

      12:00 - 12:20  |  Author(s): C. Dive

      • Abstract

      Abstract not provided

    • +

      Questions and Answers

      12:20 - 12:30

      • Abstract

      Abstract not provided

  • +

    What should non-surgeons expect from surgeons?

    • Type: Educational session
    • Presentations: 5
    • +

      Minimal requirements for surgical participation in CT screening programmes

      11:00 - 11:20  |  Author(s): G. Veronesi

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Surgeon-led randomised trials: The case of mesothelioma

      11:20 - 11:40  |  Author(s): J. Edwards

      • Abstract

      Abstract not provided

    • +

      The approach of surgeons towards N2 NSCLC

      11:40 - 12:00  |  Author(s): G. Massard

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      The impact of international surgical registries on multidisciplinary decisions: The case of thymic tumours and NET

      12:00 - 12:20  |  Author(s): P.L. Filosso

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Questions and Answers

      12:20 - 12:30

      • Abstract

      Abstract not provided

  • +

    Poster Display Session

    • Type: Poster Display Session
    • Presentations: 142
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      Tumour biology and pathology

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      4P - PD-L1 in NSCLC cytology

      12:30 - 12:30  |  Author(s): M. Kovacevic

      • Abstract

      Loading...

    • +

      5P - Repeated biopsy for mutational analysis on EGFR-mutated non-small cell lung cancer (EGFR-NSCLC): Feasibility and safety

      12:30 - 12:30  |  Author(s): G. Anguera

      • Abstract

      Loading...

    • +

      6P - Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

      12:30 - 12:30  |  Author(s): X. Wang

      • Abstract

      Loading...

    • +

      7P - Population-level effect of targeted therapy in patients with advanced pulmonary adenocarcinoma: A Swiss prospective cohort study

      12:30 - 12:30  |  Author(s): C. Schwegler

      • Abstract

      Loading...

    • +

      8P - Expression of genes associated with anti-viral response in EGFR mutant non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): N. Karachaliou

      • Abstract

      Loading...

    • +

      9P - Knockdown of MFN2 gene expression inhibits lung adenocarcinoma cell proliferation

      12:30 - 12:30  |  Author(s): Y. Lou

      • Abstract

      Loading...

    • +

      10P - In vivo evaluation of combertestatin A-4 phosphate for lung cancer by bioluminescence imaging and multispectral optoacoustic tomography

      12:30 - 12:30  |  Author(s): L. Liu

      • Abstract

      Loading...

    • +

      11P - Prognostic significance of different immunohistochemical markers in small cell lung cancer

      12:30 - 12:30  |  Author(s): E. Gkika

      • Abstract

      Loading...

    • +

      12P - Thyroid transcription factor-1 as a prognosticator in patients with metastatic lung adenocarcinoma without EGFR sensitizing mutations

      12:30 - 12:30  |  Author(s): J.Y. Park

      • Abstract

      Loading...

    • +

      13P - Characterizing the DNA damage response in putative stem cells of resected normal lung and matched NSCLC patient samples

      12:30 - 12:30  |  Author(s): T.M. Marti

      • Abstract

      Loading...

    • +

      14P - Histone H2AX phosphorylation increases apoptosis of lung cancer cells by miR-3196/PUMA pathway

      12:30 - 12:30  |  Author(s): C. Lu

      • Abstract

      Loading...

    • +

      15P - PLGF regulates crosstalk between non-small cell lung cancer cells and tumor-associated macrophages in cancer vascularization and growth

      12:30 - 12:30  |  Author(s): W. Zhang

      • Abstract

      Loading...

    • +

      16P - Carvacrol induces growth inhibition and circumvents chemoresistance via inhibition of STAT3/Skp2/p27 pathway in non-small lung cancer cells

      12:30 - 12:30  |  Author(s): K. Kim

      • Abstract

      Loading...

    • +

      Prevention, Early detection, Epidemiology, Tobacco control

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      19P - Domestic cooking fuel as a risk factor for lung cancer in women: A case control study

      12:30 - 12:30  |  Author(s): S.S. Katpattil

      • Abstract

      Loading...

    • +

      21P - The efficacy of combination therapy with varenicline and bupropion for smoking cessation

      12:30 - 12:30  |  Author(s): D.A. Johns

      • Abstract

      Loading...

    • +

      23P - Pictorial warning on cigarette packets and its role in tobacco cessation: Questionnaire survey among cigarette smokers in Chennai

      12:30 - 12:30  |  Author(s): C.J.K. Francis

      • Abstract

      Loading...

    • +

      25P - Tobacco consumption pattern among auto rickshaw drivers in Chennai city, Tamil Nadu, India

      12:30 - 12:30  |  Author(s): D.L. Francis

      • Abstract

      Loading...

    • +

      26P - Smoking habits and awareness about anti-smoking acts among general public in Gurgaon, Haryana, India

      12:30 - 12:30  |  Author(s): C.J.K. Francis

      • Abstract

      Loading...

    • +

      27P - Factors causing treatment delays and its impact on treatment outcome in patients of lung cancer: An analysis

      12:30 - 12:30  |  Author(s): D. Kumar

      • Abstract

      Loading...

    • +

      28P - Impact of a pharmaceutical consultation: Review of a pilot study

      12:30 - 12:30  |  Author(s): E. Clou

      • Abstract

      Loading...

    • +

      29P - Baseline characteristics of participants in pl-208: A multi-center trial of the prolung test™ (Transthoracic Bioconductance Measurement) as an adjunct to CT chest scans for the risk stratification of patients with pulmonary lesions suspicious for lung cancer

      12:30 - 12:30  |  Author(s): R.C. Yung

      • Abstract

      Loading...

    • +

      Translational research

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      31P - Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort

      12:30 - 12:30  |  Author(s): C. Britschgi

      • Abstract

      Loading...

    • +

      32P - Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer

      12:30 - 12:30  |  Author(s): T. Hong

      • Abstract

      Loading...

    • +

      33P - The screening and characterization of aptamer against gefitinib-resistant cells

      12:30 - 12:30  |  Author(s): Y. Chen

      • Abstract

      Loading...

    • +

      34P - Discovery of 1,3,5-triazine-monastrol based novel EGFR-tyrosine kinase inhibitor against human lung carcinoma

      12:30 - 12:30  |  Author(s): U.P. Singh

      • Abstract

      Loading...

    • +

      35P - CDK7 inhibition as a promising therapeutic strategy in lung squamous cell carcinoma with SOX2 amplification

      12:30 - 12:30  |  Author(s): J.C. Lee

      • Abstract

      Loading...

    • +

      36P - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with nivolumab

      12:30 - 12:30  |  Author(s): F. Passiglia

      • Abstract

      Loading...

    • +

      37P - Can we perform subtyping of non-small cell lung cancer patients by use of lung tissue metabolic fingerprinting?

      12:30 - 12:30  |  Author(s): M. Ciborowski

      • Abstract

      Loading...

    • +

      38P - Flow cytometry immunophenotyping of pleural fluid cytology in patients with diffuse large B-cell lymphoma (DLBCL) and malignant pleural effusion

      12:30 - 12:30  |  Author(s): F. Lumachi

      • Abstract

      Loading...

    • +

      39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models

      12:30 - 12:30  |  Author(s): U. Weinberg

      • Abstract

      Loading...

    • +

      40P - Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel

      12:30 - 12:30  |  Author(s): M. Sandelin

      • Abstract

      Loading...

    • +

      41P - Development of novel 1,2,4-triazole-thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): A. Verma

      • Abstract

      Loading...

    • +

      42P - Dual inhibitory effects of novel naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway

      12:30 - 12:30  |  Author(s): V. Kumar

      • Abstract

      Loading...

    • +

      43P - A phase I-II clinical trial to evaluate the safety, pharmacokinetics and efficacy of high dose intravenous ascorbic acid synergy with mEHT in Chinese patients with stage III-IV non-small cell lung cancer

      12:30 - 12:30  |  Author(s): J. Ou

      • Abstract

      Loading...

    • +

      Imaging and staging

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      47P - Multi detector CT evaluation of suspicious malignant lung masses with its combined wash-in & wash-out features and their histopathological correlation

      12:30 - 12:30  |  Author(s): S. Khanduri

      • Abstract

      Loading...

    • +

      48P - Evaluation of neoplasms incidentally detected by preoperative FDG-PET/CT for primary lung cancer

      12:30 - 12:30  |  Author(s): Y. Noda

      • Abstract

      Loading...

    • +

      49P - Computed tomographic features of pulmonary sarcomatoid carcinoma

      12:30 - 12:30  |  Author(s): M. Attia

      • Abstract

      Loading...

    • +

      50P - Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia

      12:30 - 12:30  |  Author(s): Y.S. Kim

      • Abstract

      Loading...

    • +

      SCLC

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis

      12:30 - 12:30  |  Author(s): H. Wang

      • Abstract

      Loading...

    • +

      53P - Systematic literature reviews of second and third-line treatments used for small-cell lung cancer (SCLC)

      12:30 - 12:30  |  Author(s): R. Goulding

      • Abstract

      Loading...

    • +

      54P - Up front chemotherapy dosing and relative dose intensity in extensive stage small cell lung cancer

      12:30 - 12:30  |  Author(s): A.W. Mølby

      • Abstract

      Loading...

    • +

      55P - Clinical significance of EBUS-TBNA in patients with small cell lung cancer

      12:30 - 12:30  |  Author(s): Y.M. Lee

      • Abstract

      Loading...

    • +

      56P - Pro-GRP in small cell lung cancer

      12:30 - 12:30  |  Author(s): S. Cavalieri

      • Abstract

      Loading...

    • +

      57P - small cell lung cancer: Retrospective review of an institution

      12:30 - 12:30  |  Author(s): A. Silva

      • Abstract

      Loading...

    • +

      58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC

      12:30 - 12:30  |  Author(s): M. Reck

      • Abstract

      Loading...

    • +

      Early stage NSCLC

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      62P - Risk factors associated with early vs late recurrence in stage I lung adenocarcinoma

      12:30 - 12:30  |  Author(s): J. Qian

      • Abstract

      Loading...

    • +

      63P - Diabetes predisposes patients to atrial fibrillation after robotic-assisted video-thoracoscopic pulmonary lobectomy

      12:30 - 12:30  |  Author(s): S. Reynolds

      • Abstract

      Loading...

    • +

      64P - Smoking history as a risk factor for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy

      12:30 - 12:30  |  Author(s): J. Glover

      • Abstract

      Loading...

    • +

      65P - Lymph node metastases in clinically node negative peripheral non-small cell lung cancer

      12:30 - 12:30  |  Author(s): T. Mehmood

      • Abstract

      Loading...

    • +

      66P - Effect of age on risk for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy

      12:30 - 12:30  |  Author(s): J. Glover

      • Abstract

      Loading...

    • +

      67P - CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: Results on 68 consecutive patients

      12:30 - 12:30  |  Author(s): D. Tosi

      • Abstract

      Loading...

    • +

      68P - Circulating tumor cells spillage after lung nodule biopsy

      12:30 - 12:30  |  Author(s): M. Sarfaty

      • Abstract

      Loading...

    • +

      69P - CT-Guided radiofrequency ablation of early stage NSCLC

      12:30 - 12:30  |  Author(s): X. Zhang

      • Abstract

      Loading...

    • +

      70P - A retrospective analysis to explore the value of gemcitabine combined with cisplatin as adjuvant chemotherapy of NSCLC

      12:30 - 12:30  |  Author(s): D. Ma

      • Abstract

      Loading...

    • +

      71TiP - A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)

      12:30 - 12:30  |  Author(s): L. Paz-Ares

      • Abstract

      Loading...

    • +

      Locally advanced NSCLC

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      75P - Predictive value of CT texture analysis in lung cancer patients undergoing nivolumab

      12:30 - 12:30  |  Author(s): V. Nardone

      • Abstract

      Loading...

    • +

      76P - Interpretation and prognostic value of PET-CT after induction chemotherapy with or without radiation in IIIA-N2 non-small cell lung cancer patients who receive curative surgery

      12:30 - 12:30  |  Author(s): J.H. Lee

      • Abstract

      Loading...

    • +

      77P - Bronchoscopic photodynamic therapy for treatment of microscopic residual disease post resection in non-small cell lung cancer

      12:30 - 12:30  |  Author(s): A. Biswas

      • Abstract

      Loading...

    • +

      78P - Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources

      12:30 - 12:30  |  Author(s): H. Pang

      • Abstract

      Loading...

    • +

      79P - Long term survival of stage IIIB non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation

      12:30 - 12:30  |  Author(s): T. Mehmood

      • Abstract

      Loading...

    • +

      80TiP - A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial

      12:30 - 12:30  |  Author(s): S. Peters

      • Abstract

      Loading...

    • +

      Advanced NSCLC

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      97P - Brigatinib in crizotinib-refractory ALK+ NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)

      12:30 - 12:30  |  Author(s): M.J. Hochmair

      • Abstract

      Loading...

    • +

      98P - Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib

      12:30 - 12:30  |  Author(s): J. Davies

      • Abstract

      Loading...

    • +

      99P - Efficacy of gefitinib in advanced squamous cell lung cancer harboring epidermal growth factor receptor mutations: A pooled analysis of individual patient data

      12:30 - 12:30  |  Author(s): D. Tao

      • Abstract

      Loading...

    • +

      100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment

      12:30 - 12:30  |  Author(s): J.C. Yang

      • Abstract

      Loading...

    • +

      101P - Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer

      12:30 - 12:30  |  Author(s): M. Sasane

      • Abstract

      Loading...

    • +

      102P - LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung

      12:30 - 12:30  |  Author(s): J.C. Yang

      • Abstract

      Loading...

    • +

      103P - Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures

      12:30 - 12:30  |  Author(s): H.J. Koo

      • Abstract

      Loading...

    • +

      104P - Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program

      12:30 - 12:30  |  Author(s): G. Metro

      • Abstract

      Loading...

    • +

      105P - Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts)

      12:30 - 12:30  |  Author(s): K.L. Reckamp

      • Abstract

      Loading...

    • +

      106P - Brain metastases (BM) development in molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials

      12:30 - 12:30  |  Author(s): S. Cedres

      • Abstract

      Loading...

    • +

      107P - The real world experience of first generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in patients with advanced lung cancer: Explorative analysis of big data from national health insurance service of Korea

      12:30 - 12:30  |  Author(s): B.S. Kwon

      • Abstract

      Loading...

    • +

      108P - NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy

      12:30 - 12:30  |  Author(s): D. Kauffmann-Guerrero

      • Abstract

      Loading...

    • +

      109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors

      12:30 - 12:30  |  Author(s): Y. Chen

      • Abstract

      Loading...

    • +

      110P - Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program

      12:30 - 12:30  |  Author(s): M. Ehmann

      • Abstract

      Loading...

    • +

      111P - Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib

      12:30 - 12:30  |  Author(s): P.K. Cheema

      • Abstract

      Loading...

    • +

      112P_PR - Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade

      12:30 - 12:30  |  Author(s): S.I. Rothschild

      • Abstract

      Loading...

    • +

      113P - Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: Interim analysis of expanded access program

      12:30 - 12:30  |  Author(s): K.K. Laktionov

      • Abstract

      Loading...

    • +

      114P - Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea

      12:30 - 12:30  |  Author(s): E.K. Cho

      • Abstract

      Loading...

    • +

      115P - Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): E. Connolly

      • Abstract

      Loading...

    • +

      116P - A randomized study to evaluate safety of DCVAC/LUCA added to chemotherapy with carboplatin and pemetrexed vs. chemotherapy alone in patients with stage IV non-small cell lung cancer

      12:30 - 12:30  |  Author(s): H. Zhong

      • Abstract

      Loading...

    • +

      117P - Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies

      12:30 - 12:30  |  Author(s): O. Roengvoraphoj

      • Abstract

      Loading...

    • +

      118P - Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients

      12:30 - 12:30  |  Author(s): C.E. Onesti

      • Abstract

      Loading...

    • +

      119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts

      12:30 - 12:30  |  Author(s): S. Thomas

      • Abstract

      Loading...

    • +

      120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): M. Reck

      • Abstract

      Loading...

    • +

      121P - Safety and efficacy of bevacizumab in "fragile" patients with advanced non-small cell lung cancer

      12:30 - 12:30  |  Author(s): C. Maragkos

      • Abstract

      Loading...

    • +

      122P - Response to Metabolically Supported Chemotherapy (MSCT) with weekly carboplatin/paclitaxel in advanced stage/metastatic (Stage IV) non-small cell lung cancer: A survival, efficacy and tolerability analysis

      12:30 - 12:30  |  Author(s): M.S. Iyikesici

      • Abstract

      Loading...

    • +

      123P - A retrospective study in Chinese patients: Is there a role of nanoparticle albumin bound paclitaxel in advanced NSCLC?

      12:30 - 12:30  |  Author(s): Y. Zhu

      • Abstract

      Loading...

    • +

      124P - Driverless lung carcinoma: Impact of expanded RNA and protein-based testing on detection of actionable biomarkers

      12:30 - 12:30  |  Author(s): Z. Gatalica

      • Abstract

      Loading...

    • +

      125P - Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma Patients (CRISP): A prospective German registry in stage IV NSCLC, AIO-TRK-0315

      12:30 - 12:30  |  Author(s): F. Griesinger

      • Abstract

      Loading...

    • +

      126P - The clinical impact of multiplex ctDNA gene analysis in lung cancer

      12:30 - 12:30  |  Author(s): S. Geva

      • Abstract

      Loading...

    • +

      127P - Prognostic significance of advanced lung cancer inflammation index (ALI) In untreated and treated stage IV non-small cell lung cancer (NSCLC): An Australian cancer centre experience

      12:30 - 12:30  |  Author(s): H. Mandaliya

      • Abstract

      Loading...

    • +

      128P - Serum DKK-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases

      12:30 - 12:30  |  Author(s): R. Qiao

      • Abstract

      Loading...

    • +

      129P - Procathepsin D as a novel diagnostic marker for malignant pleural effusion of lung cancer

      12:30 - 12:30  |  Author(s): C.Y. Lee

      • Abstract

      Loading...

    • +

      130P - EGFR mutations in lung adenocarcinoma and brain metastases: A Croatian single institution experience

      12:30 - 12:30  |  Author(s): K.B. Sreter

      • Abstract

      Loading...

    • +

      131P - T790M co-exists with other secondary resistance mechanisms in EGFR mutation positive NSCLC and are associated with inferior outcomes

      12:30 - 12:30  |  Author(s): R. Teng

      • Abstract

      Loading...

    • +

      132P - Real world treatment patterns and outcomes for mNSCLC patients receiving second and third-line therapy in Germany

      12:30 - 12:30  |  Author(s): N. Yu

      • Abstract

      Loading...

    • +

      133P - The influence of body composition on TTFields intensity in the lungs

      12:30 - 12:30  |  Author(s): U. Weinberg

      • Abstract

      Loading...

    • +

      134P - Applicable CT-guided percutaneous radiofrequency ablation (RFA) in the treatment of unresectable Lung Ground Glass Opacity (GGO)

      12:30 - 12:30  |  Author(s): Y.T. Wei

      • Abstract

      Loading...

    • +

      135P - Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant non-small cell lung cancer

      12:30 - 12:30  |  Author(s): H. Deng

      • Abstract

      Loading...

    • +

      136P - Long-term safety and efficacy of darbepoetin alfa in subjects with stage IV NSCLC receiving multi-cycle chemotherapy

      12:30 - 12:30  |  Author(s): P. Gascón

      • Abstract

      Loading...

    • +

      137P - Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in France after a first-line platinum based therapy

      12:30 - 12:30  |  Author(s): M. Pignata

      • Abstract

      Loading...

    • +

      138TiP - An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): L. Paz-Ares

      • Abstract

      Loading...

    • +

      139TiP - A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

      12:30 - 12:30  |  Author(s): M. Reck

      • Abstract

      Loading...

    • +

      140TiP - CheckMate 384: A phase 3b/4 dose-frequency optimization trial of nivolumab in advanced or metastatic non-small cell lung cancer

      12:30 - 12:30  |  Author(s): N. Reinmuth

      • Abstract

      Loading...

    • +

      141TiP - ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): P.K. Cheema

      • Abstract

      Loading...

    • +

      142TiP - A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm+ NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)

      12:30 - 12:30  |  Author(s): W. Liang

      • Abstract

      Loading...

    • +

      143TiP - IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

      12:30 - 12:30  |  Author(s): J. Jassem

      • Abstract

      Loading...

    • +

      144TiP - CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): L. Paz-Ares

      • Abstract

      Loading...

    • +

      145TiP - TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study

      12:30 - 12:30  |  Author(s): U. Weinberg

      • Abstract

      Loading...

    • +

      146TiP - EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Author(s): L. Horn

      • Abstract

      Loading...

    • +

      Metastases to and from the lung

      12:30 - 12:30

      • Abstract

      Abstract not provided

    • +

      148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis

      12:30 - 12:30  |  Author(s): F. Passiglia

      • Abstract

      Loading...

    • +

      149P - PD-L1 expression patterns in the metastatic tumors to the lung: A comparative study with the primary non-small cell lung cancer

      12:30 - 12:30  |  Author(s): Z. Gatalica

      • Abstract

      Loading...

    • +

      150P - Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer

      12:30 - 12:30  |  Author(s): D. Marinova

      • Abstract

      Loading...

    • +

      151P - Predictors of survival in patients with bone metastasis of lung cancer

      12:30 - 12:30  |  Author(s): S. Jagadeesan

      • Abstract

      Loading...

    • +

      152P - Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases

      12:30 - 12:30  |  Author(s): F. Lumachi

      • Abstract

      Loading...

    • +

      153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion

      12:30 - 12:30  |  Author(s): F. Lumachi

      • Abstract

      Loading...

    • +

      154P - Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer

      12:30 - 12:30  |  Author(s): F. Lumachi

      • Abstract

      Loading...

    • +

      155P - Combination of hepatic surgery and minimally invasive thoracic surgery using a subxyphoid approach through an abdominal incision

      12:30 - 12:30  |  Author(s): M. Lim

      • Abstract

      Loading...

    • +

      156P - Clinical outcome of cyberknife radiosurgery in brain metastases of non-small cell lung cancer: A single institutional experience

      12:30 - 12:30  |  Author(s): S. Lee

      • Abstract

      Loading...

    • +

      157P - Mediastinal masses: A study of our cases by transthoracic needle biopsy (TTNB) versus open surgery as a diagnostic procedure

      12:30 - 12:30  |  Author(s): F. Gradica

      • Abstract

      Loading...

    • +

      158TiP - Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333)

      12:30 - 12:30  |  Author(s): L. Wang

      • Abstract

      Loading...

    • +

      159TiP - TTFields and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study

      12:30 - 12:30  |  Author(s): M.P. Mehta

      • Abstract

      Loading...

    • +

      160P - BAP1 in advanced sporadic malignant pleural mesothelioma

      12:30 - 12:30  |  Author(s): A. El Bastawisy

      • Abstract

      Loading...

    • +

      161P - DKK1 stabilization as a new malignant pleural mesothelioma therapeutic avenue

      12:30 - 12:30  |  Author(s): A. Guazzelli

      • Abstract

      Loading...

    • +

      162P - Targeting the RON/MET/TAM signalling network in mesothelioma

      12:30 - 12:30  |  Author(s): A. Baird

      • Abstract

      Loading...

    • +

      164P - Heart radiation dose as a risk factor for dyspnea worsening after multimodality treatment for non-small cell lung cancer and pleural mesothelioma: An exploratory analysis

      12:30 - 12:30  |  Author(s): A. Botticella

      • Abstract

      Loading...

    • +

      165P - Malignant pleural mesothelioma: A systematic review of first-line chemotherapy and analysis of Hong Kong cohort

      12:30 - 12:30  |  Author(s): H. Pang

      • Abstract

      Loading...

    • +

      166P - Thymoma and thymic carcinoma: A real-life retrospective analysis

      12:30 - 12:30  |  Author(s): I. Attili

      • Abstract

      Loading...

    • +

      167P - Role of surgery in the treatment of thymic carcinoma based on a 5-year experience

      12:30 - 12:30  |  Author(s): F.F. Caushi

      • Abstract

      Loading...

    • +

      168P - Clinical and prognostic characteristics of primary pulmonary non-Hodgkin’s lymphoma: A retrospective analysis of 38 cases in a Chinese population

      12:30 - 12:30  |  Author(s): R. Qiao

      • Abstract

      Loading...

    • +

      169P - Pulmonary carcinoid tumors: Experience from an oncology center

      12:30 - 12:30  |  Author(s): L. Bei

      • Abstract

      Loading...

    • +

      170TiP - LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)

      12:30 - 12:30  |  Author(s): S. Popat

      • Abstract

      Loading...

  • +

    Industry Satellite Symposium 6

    • Type: Industry Satellite Symposium
    • Presentations: 1
    • Coordinates: 5/07/2017, 13:00 - 14:00, Room A
    • +

      Treatment of advanced NSCLC: State of the art today & promises for the future

      13:00 - 14:00  |  Author(s): S. Peters

      • Abstract

      Abstract not provided

  • +

    Industry Satellite Symposium 7

    • Type: Industry Satellite Symposium
    • Presentations: 1
    • Coordinates: 5/07/2017, 13:00 - 14:00, Room C
    • +

      Sharing our knowledge in NSCLC: Case interchange of real-world experience

      13:00 - 14:00  |  Author(s): R..A. Stahel

      • Abstract

      Abstract not provided